Please login to the form below

Combination treatment

This page shows the latest Combination treatment news and features for those working in and with pharma, biotech and healthcare.

Sanofi gains access to antibody tech with Kymab acquisition

Aside from KY1005, Kymab’s pipeline also includes an early-stage oncology candidate – KY1044 – which is currently being investigated as a monotherapy treatment and in combination with a PD-L1 inhibitor. ... The Kymab acquisition adds KY1005 to our

Latest news

Roche’s tiragolumab plus Tecentriq combo wins FDA breakthrough therapy designation

The BTD covers the combination treatment in the first-line setting for people with metastatic non-small cell lung cancer (NSCLC), whose tumours have high PD-L1 expression and no EGFR ... Results from this study showed that, after an average follow-up of
Roche gets EU approval for fixed-dose Herceptin/Perjeta combination

The new combination treatment, containing Herceptin (trastuzumab) and Perjeta (pertuzumab) with hyaluronidase, has been authorised for use for the treatment of early and metastatic HER2-positive breast cancer. ... This means that the combination
Lilly’s repurposed COVID-19 med baricitinib bags FDA emergency approval

Drug approved for emergency use in combination with Gilead's remdesivir. Eli Lilly and Incyte’s arthritis treatment baricitinib has been repurposed as a COVID-19 treatment, scoring an emergency use ... The EUA covers baricitinib in combination with
Moderna posts encouraging early data for personalised cancer vaccine

In terms of median progression-free survival (mPFS), the combination treatment reached 9.8 months – in comparison, the published ORR and mPFS for Keytruda monotherapy are 14.6% and 2.0 ... A phase 1 trial is about safety first and foremost, and we now
Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer

The combination treatment also met key secondary endpoints of overall survival (OS) and objective response rate (ORR). ... Merck already has approval for another combination treatment, Keytruda plus Inlyta (axitinib), for the first-line treatment of

More from news
Approximately 0 fully matching, plus 285 partially matching documents found.

Latest Intelligence

As COVID-19 takes over the world, biopharma fights back

A combination HIV treatment: AbbVie’s Kaletra. In an unprecedented move, AbbVie has suspended its patents on its combination HIV drug Kaletra, after it was identified as having potential against ... The combination drug was first included in Chinese
Deal Watch April 2016

Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 85 . Dong A (SK). Tobira (US). Cross license. Evogliptin
Pharma deals in April 2015

No deal terms were disclosed. The initial development plan will look at the combination therapy as a potential treatment for NHL. . ... The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid.
Pharma deals during July 2014

Underscoring its strategy in focusing the business in the core areas, in July Baxter also announced the acquisition of AesRx, a private US company developing a phase II stage prophylactic treatment ... The acquisition of Almirall's respiratory business
Interview: AstraZeneca's Susan Galbraith

And again, matching drugs that work well together will be crucial going forward: “Combination treatment will be a critical component; how best to put these drugs together with other checkpoint inhibitors, ... This includes people with NSCLC who have a

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

Oncosec

body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; ... Results from recently completed
Marketing strategy in complex environments

The last few years have seen influential scientific advances, resulting in subtle shifts in how pharma tackles disease treatment. ... The treatment of aggressive diseases often benefits very noticeably from combination therapy, especially when involving

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Healthcare Lead Copywriter: Competitive

Healthcare Senior Account Manager: Competitive

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Account Director – Creative Healthcare Communications: Competative

Medical Editor: Competitive

Healthcare Account Director: Competitive

PMHub

Add my company

BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

The search for effective drug treatments for COVID-19: PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
AstraZeneca’s focus on diagnosing and managing chronic kidney disease: People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story: How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....